Sareum Holdings PLC have published Final Year Results. We have published research on this which is attached and a snapshot of the research is below.
The specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of autoimmune diseases and cancer, announced its results for the year ended 30 June 2021. It has been a period of significant progress for its selective TYK2/JAK1 Inhibitors, which have reported further strong pre-clinical results, attra ....
25 Oct 2021
Hybridan Research: 25/10/21: Sareum Holdings PLC: Optimising value potential of TYK2/JAK1 programmes ahead of planned clinical submission in 2022
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hybridan Research: 25/10/21: Sareum Holdings PLC: Optimising value potential of TYK2/JAK1 programmes ahead of planned clinical submission in 2022
Sareum Holdings plc (SAR:LON) | 28.5 0.5 6.5% | Mkt Cap: 28.9m
- Published:
25 Oct 2021 -
Author:
Derren Nathan -
Pages:
8
Sareum Holdings PLC have published Final Year Results. We have published research on this which is attached and a snapshot of the research is below.
The specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of autoimmune diseases and cancer, announced its results for the year ended 30 June 2021. It has been a period of significant progress for its selective TYK2/JAK1 Inhibitors, which have reported further strong pre-clinical results, attra ....